Clinical trial
Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy
NCT00056576 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00056576 |
|---|---|
| Title | Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy |
| Official title | A Double-Blind, Randomized, Multicenter, Parallel Group Study to Establish Dose-Response, Safety, and Efficacy of Zonegran (Zonisamide) as Monotherapy in Patients With Newly Diagnosed Epilepsy |
| Lead sponsor | Eisai Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Epilepsy, Complex Partial |
| Intervention type | Drug |
| Interventions | Zonisamide |
| Enrollment | 165 |
| Start date | Feb 1, 2002 |
| Primary completion | Oct 1, 2004 |
| Completion | Oct 1, 2004 |
| First posted | Mar 19, 2003 |
| Last update posted | Jul 18, 2011 |
| Countries | Estonia, Hungary, Lithuania, Ukraine, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: